Issue Date: October 9, 2017
Cambrex bucks the pharmaceutical service trend
The world of pharmaceutical contract manufacturing has been rocked by a number of jarring deals of late. Thermo Fisher Scientific’s acquisition of Patheon, valued at $7.2 billion, was a shock to many industry watchers earlier this year. Lonza’s $5.5 billion purchase of Capsugel also made a stir, as did the merger of Cambridge Major Laboratories and AAIPharma Services to form Alcami. Even . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society